Crox can have a technical rebound, but the next fall, $ 4 / $ 5.00.
The autumn and winter season is its worst sales
CTI BioPharma Corp (NASDAQ:CTIC) EVP Jack W. Singer sold 15,000 shares of the business's stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $1.64, for a total value of $24,600.00. Following the transaction, the executive vice president now directly owns 1,451,850 shares in the company, valued at $2,381,034. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
September 17th, 2015
Shares of Marvell Technology Group (NASDAQ:MRVL) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 5,735,484 shares, a decline of 23.6% from the August 14th total of 7,507,513 shares, Analyst Ratings Net reports. Based on an average daily volume of 6,925,146 shares, the short-interest ratio is currently 0.8 days. Approximately 1.4% of the company’s stock are short sold.
They now have a "market underperform" rating on the stock. 18.7% downside from the previous close of $8.62
Infoblox (NASDAQ:BLOX) VP David Nicholas Gee sold 5,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $19.32, for a total transaction of $96,600.00. Following the completion of the transaction, the vice president now directly owns 36,766 shares in the company, valued at $710,319.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Sentiment: Strong Sell
Immunomedics reports FQ4 and FY15 results
Aug 20 2015, 07:18 ET | By: Mamta Mayani, SA News Editor
Immunomedics (IMMU -4.7%) FQ4 results: Revenues: $2.4M (+100.0%); Operating Expenses: $13.6M (+3.8%); Operating Loss: ($11.2M) (+5.9%); Net Loss: ($12.4M) (-5.1%); Loss Per Share: ($0.13) (unch).
FY2015 results: Revenues: $5.7M (-36.7%); Operating Expenses: $51.9M (+16.4%); Operating Loss: ($46.2M) (-29.8%); Net Loss: ($48M) (-35.6%); Loss Per Share: ($0.51) (-21.4%); Quick Assets: $99.6M (+138.3%).
No guidance given
Sentiment: Strong Sell
August 10, 2015 10:37 AM EDT
Deutsche Bank downgraded Petrobras (NYSE: PBR) from Hold to Sell with a price target of BRL 8.60. Analyst Alexander Burgansky warned of deteriorating financial conditions and a reduced dividends outlook.
"Barring higher oil prices, we estimate Petrobras will face deteriorating financial conditions with net debt/EBITDA possibly exceeding 6.0 in 2016 at the same time that its funding needs accelerate to $16-20bn pa. This may necessitate further capex/growth reductions, particularly if Brazil's and/or Petrobras’s credit ratings are downgraded to below investment grade. At the same time, government/policy help has become less likely with a challenging macro environment in Brazil. We lower our target price by 30% and cut our dividend expectations for the ordinary shares to nil," said Burgansky.
"To fully fund its capex and interest in 2016, we estimate Petrobras needs a Brent oil price of $85/bbl and full parity pricing in Brazil – this would imply average increases in domestic gasoline and diesel prices of c.50% vs. current levels – a scenario that looks increasingly unlikely to us, despite the company’s stated commitment to parity pricing," added the analyst.
Burgansky added, "We now expect the company’s dividends to be reduced to the absolute minimum. We now do not expect an ordinary dividend until the Brent oil price exceeds $70/bbl. At the same time, we believe the company will revert to paying a dividend on the preferred shares for 2015, in line with its charter."
For an analyst ratings summary and ratings history on Petrobras click here. For more ratings news on Petrobras click here.
Shares of Petrobras closed at $6.05 yesterday
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating: N/A (Score: NaN)
Consensus Price Target: N/A
TherapeuticsMD Reports Q2 EPS $(0.16) vs. Est. $(0.11), Rev. $4.8M vs. Est. $4.65M
Lanphier Edward O Ii, director officer (President & CEO) of Sangamo Biosciences Inc, unloaded 25,000 shares at an average price of $10.43 on July 15, 2015. The total amount of the transaction was worth $260,750 BIG RAT!!
Lies have short, legs sooner or later the truth comes to light. Big Rats!
Good for ZIOP
4:03 pm ET Bezinga
August 03, 2015 02:54 PM Eastern Daylight Time
CHICAGO--(BUSINESS WIRE)--InnerWorkings, Inc. (NASDAQ: INWK), the leading marketing execution firm, has expanded its marketing execution partnership with Gannett Co., Inc. (NYSE: GCI). Under the new multi-year agreement, InnerWorkings will exclusively manage Gannett’s direct response team and will provide a comprehensive solution for marketing execution – from creative ideation and design through production.
“This step will strengthen our long-term partnership by giving Gannett the opportunity to benefit further from the flexibility of our growing creative services team”
Gannett expanded its relationship based on InnerWorkings’ longstanding track record of improving direct response capabilities while managing Gannett’s U.S. consumer marketing print operations. InnerWorkings’ creative services team of 30 design professionals will sit onsite at Gannett and collaborate with InnerWorkings’ current print management team to enhance accountability, shorten turnaround times, and optimize marketing efforts.
InnerWorkings’ creative services team will offer end-to-end creative execution, including graphic design, creative ideation, versioning, copywriting, and pre-press support. Gannett will benefit from efficiencies in its marketing operations and InnerWorkings’ proven expertise as a direct marketer.
“This step will strengthen our long-term partnership by giving Gannett the opportunity to benefit further from the flexibility of our growing creative services team,” said Harris Atkins, Senior Vice President of Business Development at InnerWorkings. “Together, our creative execution, direct marketing, and total production expertise provide Gannett with a one-stop partnership that brings new ideas, efficient operations, and quality at every turn.”
6:24 am ET
*Crocs Sees Q3 Sales $280M to $290M vs $293.9M est
6:18 am ET
Crocs Inc. 2Q Net $9.7M CROX
6:18 am ET
Crocs Inc. 2Q EPS 11c CROX
6:17 am ET
Crocs Inc. 2Q Rev $345.7M CROX
6:15 am ET
*Crocs Q2 GAAP EPS $0.11, Revenue $346M vs $345M est
7:30 am ET
Crocs 2Q EPS 11c CROX
7:30 am ET
Crocs 2Q Rev $345.7M CROX
7:30 am ET
Crocs 2Q Net $13.4M CROX
7:34 am ET
Crocs 2Q Non-GAAP Net $27.3 Million CROX
7:33 am ET
Crocs Sees 3Q Rev $280M-$290M CROX
CROX:At any time, again $ 10.00/$1100
Markit short selling activity: MEDIUM
We are talking about $66M /$55M less in Q3. EPS can be negative!